Literature DB >> 2532457

Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system. Endogenous antagonists.

C I Johnston1, P G Hodsman, M Kohzuki, D J Casley, B Fabris, P A Phillips.   

Abstract

The biologic actions of the cardiac peptide hormone atrial natriuretic peptide (ANP) of vasorelaxation, diuresis and natriuresis, suppression of aldosterone, vasopressin release, and thirst are the opposite of those of the renin angiotensin system. This close relationship is further strengthened by the complementary localization of their receptors in the brain, adrenal gland, vasculature, and kidney. In many physiologic situations including postural changes, volume expansion, water immersion, high altitude, and lower body negative pressure, the plasma levels of ANP and angiotensin II change inversely. In congestive heart failure, renin and aldosterone levels may initially be suppressed by high levels of ANP. Similarly the low renin levels associated with increasing age and with elderly hypertensive patients, may be the result of the elevation of plasma ANP that occurs with aging. ANP may thus be the endogenous antagonist of the renin angiotensin aldosterone system. These two opposing systems allow fine-tuning of volume and pressure by the body.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2532457     DOI: 10.1016/0002-9343(89)90087-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  17 in total

1.  An ab initio quantum mechanical drug designing procedure: application to the design of balanced dual ACE/NEP inhibitors.

Authors:  Nishi K Rao; Arpita Yadav; Sanjeev Kumar Singh
Journal:  J Mol Model       Date:  2009-05-09       Impact factor: 1.810

Review 2.  Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.

Authors:  E Kubota; R G Dean; R A Hubner; L C Balding; C I Johnston; L M Burrell
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

3.  Interactions between atrial natriuretic peptide and the renin-angiotensin system during salt-sensitivity exhibited by the proANP gene-disrupted mouse.

Authors:  Ekaterini Angelis; M Yat Tse; Stephen C Pang
Journal:  Mol Cell Biochem       Date:  2005-08       Impact factor: 3.396

Review 4.  Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism.

Authors:  I David Weiner
Journal:  Semin Nephrol       Date:  2013-05       Impact factor: 5.299

5.  Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide.

Authors:  Karim Sabrane; Markus N Kruse; Larissa Fabritz; Bernd Zetsche; Danuta Mitko; Boris V Skryabin; Melanie Zwiener; Hideo A Baba; Masashi Yanagisawa; Michaela Kuhn
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

6.  Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure.

Authors:  Rita Holtwick; Michael Gotthardt; Boris Skryabin; Martin Steinmetz; Regine Potthast; Bernd Zetsche; Robert E Hammer; Joachim Herz; Michaela Kuhn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

Review 7.  Vasopeptidase inhibitors: will they have a role in clinical practice?

Authors:  Matthew I Worthley; Roberto Corti; Stephen G Worthley
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

Review 8.  Age-Related Sleep Disruption and Reduction in the Circadian Rhythm of Urine Output: Contribution to Nocturia?

Authors:  Jeanne F Duffy; Karine Scheuermaier; Kevin R Loughlin
Journal:  Curr Aging Sci       Date:  2016

9.  B-type natriuretic peptide levels and insulin resistance in patients with severe ischemic myocardial dysfunction.

Authors:  F Tassone; L Gianotti; F Rolfo; G Visconti; G Borretta; M Feola
Journal:  J Endocrinol Invest       Date:  2009-03-25       Impact factor: 4.256

10.  Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial.

Authors:  Vibhu Parcha; Nirav Patel; Rajat Kalra; Sarabjeet S Suri; Garima Arora; Thomas J Wang; Pankaj Arora
Journal:  J Am Heart Assoc       Date:  2021-03-23       Impact factor: 6.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.